PubMed Health⌕ Search

Biomedical subjects

Y Beigel

Publications and source records attributed to Y Beigel.

34 records · Page 2Linked to original sources

Hepatic infarction in a patient with the lupus anticoagulant.

We describe a 31-year-old patient with missed abortion, thrombocytopenia, and clinical, laboratory, and radiologic evidence of hepatic infarction. On evaluation, she was found to have the lupus anticoagulant. The association between enhanced thrombosis and the lupus anticoagulant is discussed, and previously reported thrombotic complications are described. The etiology, clinical course, and radiologic features of liver infarction are summarized, and the importance of recognizing and treating this form of hypercoagulability is stressed. To our knowledge, this is the first description of liver infarction associated with the lupus anticoagulant.

Adult↗

Musculoskeletal manifestations in patients with hypercholesterolemia.

Musculoskeletal symptoms were assessed in 33 patients with familial and 36 patients with nonfamilial type IIa hypercholesterolemia and compared to 33 healthy controls. Significant joint pain was reported by 47.8% of the patients with hypercholesterolemia vs 25.8% of the control group. Pain in the hyperlipidemic patients was significantly more prevalent in ankles and feet compared to the control group. The pain was not due to local effects of xanthoma, and was not accompanied by symptoms of inflammation or systemic rheumatic symptoms such as morning stiffness.

Adult↗

Plasma catabolism of human apolipoprotein E isoproteins: lack of conversion of the doubly sialylated form to the asialo form in plasma.

Apolipoprotein E (apoE) circulates as a mixture of sialylated and asialylated forms. In this study the catabolic fate and the plasma turnover rate of the different apoE forms have been investigated in vivo in humans. Asialo apoE (E) and doubly sialylated apoE (Ess) were isolated by preparative isoelectrofocusing from the VLDL of subjects homozygous for the E3 allele. 131E3 and 125E3ss were injected simultaneously into three hypertriglyceridemic subjects, and plasma samples were collected up to the sixth day. VLDL were isolated by ultracentrifugation, and the apoE forms were separated by isoelectrofocusing. Gel bands corresponding to E3 and E3ss were cut out and counted for the associated radioactivity. Residence times in plasma for 131E3 and 125E3ss were 0.95 +/- 0.16 and 0.74 +/- 0.16 days, respectively. As determined from the gel count distribution up to 24 hours, no conversion of the injected sialylated form to the correspondent asialylated form was detected.

Aged↗

Urinary amine metabolite excretion in a patient with adrenergic hyperactivity state: reaction to phenelzine withdrawal and combined treatment.

Urinary MHPG (3-methoxy-4-hydroxyphenylglycol) amounts increased threefold during a toxic delirious state in a 57-year-old bipolar patient 3 days after phenelzine treatment was stopped. This norepinephrine metabolite was not expected to rise as monoamine oxidase (MAO) was completely blocked. In addition, the delirious state appeared as a rebound phenomenon and not an acute toxic state during drug administration. It seems that phenelzine acts more through catecholamine release phenomenon than by inhibition of MAO.

Bipolar Disorder↗

Plasma metabolism of apolipoprotein A-IV in humans.

As assessed by molecular sieve chromatography and quantitation by a specific radioimmunoassay, apoA-IV is associated in plasma with the triglyceride-rich lipoproteins, to a high density lipoprotein (HDL) subfraction of smaller size than HDL3, and to the plasma lipoprotein-free fraction (LFF). In this study, the turnover of apoA-IV associated to the triglyceride-rich lipoproteins, HDL and LFF was investigated in vivo in normal volunteers. Human apoA-IV isolated from the thoracic duct lymph chylomicrons was radioiodinated and incubated with plasma withdrawn from normal volunteers after a fatty meal. Radioiodinated apoA-IV-labeled triglyceride-rich lipoproteins, HDL, and LFF were then isolated by chromatography on an AcA 34 column. Shortly after the injection of the radioiodinated apoA-IV-labeled triglyceride-rich lipoproteins, most of the radioactivity could be recovered in the HDL and LFF column fractions. On the other hand, when radioiodinated apoA-IV-labeled HDL or LFF were injected, the radioactivity remained with the originally injected fractions at all times. The residence time in plasma of 125I-labeled apoA-IV, when injected in association with HDL or LFF, was 1.61 and 0.55 days, respectively. When 125I-labeled apoA-IV was injected as a free protein, the radioactivity distributed rapidly among the three plasma pools in proportion to their mass. The overall fractional catabolic rate of apoA-IV in plasma was measured in the three normal subjects and averaged 1.56 pools per day. The mean degradation rate of apoA-IV was 8.69 mg/kg X day. The results are consistent with the conclusions that: apoA-IV is present in human plasma in three distinct metabolic pools; apoA-IV associated with the triglyceride-rich lipoproteins is a precursor to the apoA-IV HDL and LFF pools; apoA-IV in LFF is not a free protein and its turnover rate is faster than that of apoA-IV in HDL; since no transfer of apoA-IV from the HDL or the LFF occurs, these pools may represent a terminal pathway for the catabolism of apoA-IV; and the catabolism of apoA-IV in HDL is dissociated from that of apoA-I although both apoproteins may reside on the same lipoprotein particles.

Apolipoprotein A-I↗

Impairment of induction of delta-aminolevulinic acid synthase by gluconeogenic amino acids and carbohydrates in vitro.

This study was undertaken in a system of chick embryo liver cells incubated in Earle's Basal Salt Solution with hormones. Impairment of induction of delta-aminolevulinic acid synthase (ALAS) by allyl-isopropylacetamide (AIA) was observed in the presence of glucose. Fructose and various gluconeogenic substances including gluconeogenic amino acids had a similar effect. Leucine, which is purely ketogenic, did not influence induction of ALAS. SH-containing amino acids increased induction of ALAS by AIA. The glucose analogues 3-O-methylglucose and 2-deoxyglucose did not impair induction of ALAS by AIA. The inhibitory effect of glycerol, fructose, and glycine was not affected by 3-O-methylglucose but was reversed by 2-deoxyglucose. The results indicate that the salutary effects of proteins on acute attacks of hepatic porphyria are probably caused by their gluconeogenic properties and that glucose-6-phosphate, or metabolite of glucose-6-phosphate that is not in the glycolytic pathway, is the active agent that leads to the glucose-like effect.

3-O-Methylglucose↗

The porphyrogenic effects of calcium channel blocking drugs.

Treatment of monolayers of chick embryo hepatocytes with the calcium channel blocking drugs nifedipine and verapamil resulted in a decrease in the activity of uroporphyrinogen decarboxylase, an increase in the activity of delta-aminolaevulinate synthase and accumulation of porphyrins with uroporphyrin and heptacarboxylic porphyrin predominating. Diltiazem, another calcium channel blocking drug, did not affect uroporphyrinogen decarboxylase activity and had a slight effect only on the accumulation of porphyrins. Experiments with nifedipine and verapamil in the presence of various concentrations of calcium indicate that the porphyrogenic effect is apparently not related to blocking of calcium channels.

5-Aminolevulinate Synthetase↗

Hypocalcaemia, a possible manifestation of thyrotoxicosis.

A severely thyrotoxic patient was found to have hypocalcaemia and tetany, which cleared when she became euthyroid. Cessation of treatment with propranolol and propylthiouracil resulted in a recurrence of the thyrotoxicosis and the reappearance of hypocalcaemia. Reinstitution of treatment resulted in a second remission of the thyrotoxicosis and correction of the hypocalcaemia. It is suggested that in this patient, the thyrotoxicosis was the cause of hypocalcaemia. The various pathogenetic mechanisms are discussed.

Female↗

Cholesterol turnover and metabolism in two patients with abetalipoproteinemia.

Total body turnover of cholesterol was studied in two patients with abetalipoproteinemia, a 32-year-old man and a 31-year-old woman. The patients received [14C]cholesterol intravenously, and the resulting specific activity-time curves (for 40 and 30 weeks, respectively) were fitted with a three-pool model. Parameters were compared with those from studies of cholesterol turnover in 82 normal and hyperlipidemic subjects. A three-pool model gave the best fit for the abetalipoproteinemic patients, as well as for the 82 previously studied subjects, suggesting general applicability of this model. Cholesterol production rates in the two abetalipoproteinemic subjects (0.82 and 0.89 g/day) were close to values predicted for persons of their body weight. Thus, total body turnover rate of cholesterol was quite normal in abetalipoproteinemia, confirming previous reports. Very low values (9.2 and 8.4 g) were found for M1, the size of the rapidly exchanging compartment pool 1, in the two abetalipoproteinemic subjects. These values were well below the values predicted (from the comparison study population) for normal persons of this size with low plasma cholesterol levels. For one patient, total body exchangeable cholesterol was very low, although not significantly below the predicted values for a person of his size. In the second patient, the observed estimate for total body exchangeable cholesterol was well within the range of values predicted for persons of her size with low to extremely low cholesterol levels.(ABSTRACT TRUNCATED AT 250 WORDS)

Abetalipoproteinemia↗

Eosinophilic pleural effusion with high anti-DNA activity as a manifestation of systemic lupus erythematosus.

A patient, known to have systemic lupus erythematosus (SLE), presented with an eosinophilic pleural effusion. It is believed that SLE was the cause of her pleural effusion as increased levels of anti-DNA activity were found in the pleural fluid. Eosinophilic pleural effusion is a previosuly unreported observation in SLE patients (so far as the authors are aware), and the existence of increased anti-DNA activity in the pleural fluid may have value as an additional aid in the diagnosis of this disease.

Antibodies, Antinuclear↗

The significance of paraproteinemia in hairy cell leukemia: case report and review of the literature.

A case of hairy cell leukemia and IgG paraproteinemia is described. Peripheral blood surface marker analysis, serum paraprotein levels and immunoperoxidase stains of bone marrow sections at diagnosis and after 7 months of interferon treatment suggested the existence of two unrelated pathological B cell clones: one composed of malignant hairy cells and the other secreting the paraprotein. Previously reported cases of hairy cell leukemia with paraproteins are reviewed and our patient's contribution to the understanding of this association is stressed.

Aged↗